Gynecological Cancers - Niche opportunities in advanced disease

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2006-12-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Cases of endometrial cancer are set to rise in developed countries due to an increase in risk factors such as obesity. In contrast, while incidence of cervical cancer is set to decrease in developed countries following the implementation of anti-HPV immunization with Merck & Co's Gardasil and GlaxoSmithKline's Cervarix, it will remain a major cause of cancer-related death in the developing world.


Scope

  • Current diagnosis and treatment of endometrial, cervical, vaginal and vulvar cancer, including treatment regimens by stage of disease
  • Issues and unmet needs in current treatment, screening and potential anti-HPV vaccination programs
  • Examination of pipeline activity and potential future opportunities for drug developers
  • Stakeholder opinions and interview transcripts based on qualitative interviews with five opinion leaders from the US and Europe


    • Report Highlights
    The advent of anti-HPV vaccines capable of preventing cervical cancer, Merck & Co's Gardasil and GlaxoSmithKline's Cervarix, represent a major breakthrough, capable of significantly reducing the burden of disease. However, maximal impact will depend on the ease by which cash-strapped developing countries are able to gain access to these vaccines.

    Despite being the most common of the gynecological malignancies, drug development for endometrial cancer is minimal. Given the high rate of early diagnosis and cure, the development of systemic therapies for metastatic disease has not been prioritized. This relatively inactive pipeline may become more of an issue as disease incidence increases.

    While ample Phase I/II clinical trial data has been reported for the gynecological malignancies, only a small number of Phase III studies have been completed to corroborate earlier results. To fully define treatment strategies and provide solid evidence for clinical decision making, more large-scale, randomized clinical trials are necessary.


    Reasons to Purchase

  • Identify the limitations of current therapy for gynecological cancer and the potential of future therapy
  • Understand current epidemiological trends in gynecological cancer and ongoing treatment controversies
  • Assess the opportunities for innovative targeted therapies in gynecological cancer, particularly in metastatic disease

    • Table of Contents

    Other users found this report page using the following search terms: ovarian cancer breast cancer cervical cancer uterine cancer cancer cancers vulvar gemzar incidence advanced cisplatin topotecan disease niche

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.